What is your treatment approach for a pediatric patient with H3K27M-mutant diffuse midline glioma following progression after radiation therapy?
Do you consider targeted therapy (e.g., dordaviprone)?
Community PollStarted
Is dordaviprone part of your standard approach to patients with DMG and H3 K27M mutation who have progressed post-radiation?
14 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Colorado Anschutz Medical Campus
Answered on
First, if the patient is at least six months from initial radiation and has had a reasonable initial response, reirradiation is the best proven treatment for recurrence. We would also encourage enrollment on a clinical trial (the DMG National Tumor Board is a helpful resource for determining for whi...
Join for free or sign in to see the full answer